Common Stock, par value $0.001
- Symbol
- BTAI
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Historical · closed Sep 4, 2026
Current Report · Items 2.02, 9.01 · 8-K
BioXcel Therapeutics, Inc.
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 27, 2026, BioXcel Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months and year ended December 31, 2025 and provided a business update. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.…
Company context
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.
Current securities
Historical securities (1)
Recent company filings
- Completion of Acquisition or Disposition of Assets · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearOct 30, 2026
- Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingSep 1, 2026
- Entry into a Material Definitive Agreement · Bankruptcy or ReceivershipAug 28, 2026
- Entry into a Material Definitive AgreementAug 25, 2026
- Entry into a Material Definitive AgreementAug 24, 2026
Registered securities in this filing
BioXcel Therapeutics, Inc. · 8-K · Filed 2026-03-27
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On March 27, 2026, BioXcel Therapeutics, Inc.
(the “Company”) issued a press release announcing its financial results for the three months and year ended December 31,
2025 and provided a business update. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K and incorporated herein by reference.
The information disclosed under this Item 2.02,
including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant
to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
Filed exhibits (1)
EX-99.1 2 tm269970d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports potential approval as early as year-end 2026 Advancing commercial and launch plans based on third-party market assessment NEW HAVEN, Conn., March 27, 2026 - BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today reported financial results for the fourth quarter and full-year 2025 and provided an update on its late-stage pipeline and commercial launch readiness plans. The Company submitted a supplemental New Drug Application (sNDA) in January to the U.S. Food and Drug Administration (FDA) seeking label expansion of IGALMI for the acute treatment of agitation associated with bipolar disorders and schizophrenia in the at-home setting. The Company is also de…
Open exhibit ↗